Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$62,293 | -$27,029 | -$41,307 | -$43,241 |
| Dep. & Amort. | $85 | $151 | $367 | $460 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $3,003 | $2,147 | $2,692 | $4,232 |
| Change in WC | -$1,647 | -$3,594 | $1,412 | -$3,236 |
| Other Non-Cash | $35,428 | $4,390 | $9,813 | $5,070 |
| Operating Cash Flow | -$25,424 | -$23,935 | -$27,023 | -$36,715 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$34 | -$269 | -$5 |
| Net Acquisitions | $5 | $0 | $22 | -$22 |
| Inv. Purchases | -$70,119 | -$47,048 | -$66,191 | -$9,357 |
| Inv. Sales/Matur. | $42,630 | $62,623 | $43,162 | $30,922 |
| Other Inv. Act. | $0 | $0 | $0 | $22 |
| Investing Cash Flow | -$27,484 | $15,541 | -$23,276 | $21,560 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $16,405 | $7,843 | $0 | $60,943 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $32,623 | $12 | $0 | $1,215 |
| Financing Cash Flow | $49,028 | $7,855 | $0 | $62,158 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$3,880 | -$539 | -$50,299 | $47,003 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $12,620 | $13,159 | $63,458 | $16,455 |
| End Cash | $8,740 | $12,620 | $13,159 | $63,458 |
| Free Cash Flow | -$25,424 | -$23,969 | -$27,292 | -$36,720 |